

Fax completed form to: (855) 840-1678
If this is an URGENT request, please call (800) 882-4462 (800.88.CIGNA)

Sunosi (solriamfetol) Wakix (pitolisant)

PHYSICIAN INFORMATION			PATIENT INFORMATION				
* Physician Name: Specialty: * DEA, NPI or TIN:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this				
	DEA, NI	TOT THV.	form are completed.*				
Office Contact Person:			* Patient Name:				
Office Phone:			* Cigna ID: * Date of Birth:				
Office Fax:			* Patient Street Address:				
Office Street Address:			City:	State	:	Zip:	
City:	State:	Zip:	Patient Phone:				
Urgency: ☐ Standard ☐ Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)							
Medication requested: ICD10: ☐ Sunosi 75mg ☐ Sunosi 150mg ☐ Wakix 4.45mg ☐ Wakix 17.8mg ☐ Other (please specify):							
Directions for use:	irections for use: Quantity requested:						
Is this a new start or continuation of therapy? If your patient has already begun treatment with drug samples, please choose new start of therapy. ☐ new start of therapy ☐ continued therapy							
(if continued therapy) Has your patient had a positive response to therapy with this drug? Notes: You may answer yes if there is a previously approved authorization, overturned appeals, or paid pharmacy claims for this medication. □ Yes □ No							
(if Sunosi requested) Is this drug being prescribed by or in consultation with a neurologist, pulmonologist or sleep specialist?							
Yes No (if Sunosi requested) Please provide clinical support for any dosing over 1 tablet/day, including past doses tried and results:							
(if Wakix requested) Is this drug being prescribed by or in consultation with a neurologist or sleep specialist? ☐ Yes ☐ No (if Wakix requested) Please provide clinical support for any dosing over 2 tablet/day, including past doses tried and results:							
Urgency: ☐ Standard			ing this box, I attest to the fact that operative the customer's life, heal				
Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient?							
Diagnosis related to use: □ excessive daytime sleepiness associated with narcolepsy □ excessive daytime sleepiness associated with obstructive sleep apnea (OSA) □ other (please specify):							
Clinical Information:							
For Wakix ONLY: This drug requires supportive documentation (chart notes, sleep study, etc). Supportive documentation for all answers must be attached with this request							
(if Wakix) Did your patient have ANY of the following tests: ☐ polysomnogram (PSG) ☐ multiple sleep latency test (MSLT)?							

☐ Yes, ONLY a polysomnogram (PSG) ☐ Yes, ONLY a multiple sleep latency test (MSLT) ☐ Yes, BOTH a polysomnogram (PSG) and a multiple sleep latency test (MSLT) ☐ No, neither of the above	
(if Wakix) Has your patient had a documented failure/inadequate response, intolerance, OR does your patient have a per FDA label or is not a candidate (for example, individual has a history of misuse or abuse of controlled substances following: A) armodafinil (generic for Nuvigil) OR-	
B) modafinil (generic for Provigil)?	☐ Yes ☐ No
Will the patient use stimulant medications (for example, armodafinil, amphetamine, dextroamphetamine/ amphetamine methylphenidate, modafinil, solriamfetol) in combination with Wakix for narcolepsy? Notes: Nuvigil is brand armodafinil; Adzenys XR-ODT, Adzenys ER, Dyanavel XR, Evekeo are brand amphetamine; Adhansia XR, Concerta, Cotempla XR-ODT, Daytrana, Jornay PM, QuilliChew ER, Quillivant XR, Ritalin, Ritalin LA a methylphenidate; Provigil is brand modafinil; Sunosi is brand solriamfetol	
(if Sunosi and narcolepsy) Does your patient have documented failure/ inadequate response or intolerance to ONE of A) amphetamine (generic for Evekeo) B) Armodafinil (generic for Nuvigil) OR modafinil (generic for Provigil) C) dextroamphetamine/amphetamine (generic for Adderall) D) dextroamphetamine (generic for Dexedrine or Zenzedi) OR ProCentra (dextroamphetamine solution) E) methylphenidate chewable tablet OR methylphenidate tablet (generic for Ritalin) OR methylphenidate oral solution Methylin)?	•
(if no) Does your patient have contraindication per FDA label or is NOT a candidate for ONE of the following A) amphetamine (generic for Evekeo) B) Armodafinil (generic for Nuvigil) OR modafinil (generic for Provigil) C) dextroamphetamine/amphetamine (generic for Adderall) D) dextroamphetamine (generic for Dexedrine or Zenzedi) OR ProCentra (dextroamphetamine solution) E) methylphenidate chewable tablet OR methylphenidate tablet (generic for Ritalin) OR methylphenidate ora for Methylin)?	
(if Sunosi and OSA) Does your patient have documented failure/ inadequate response or intolerance to ONE of the for A) armodafinil (generic for Nuvigil)	llowing:
-OR- B) modafinil (generic for Provigil)?	☐ Yes ☐ No
(if no) Does your patient have contraindication per FDA label or is NOT a candidate for ONE of the following A) armodafinil (generic for Nuvigil) -OR-	:
B) modafinil (generic for Provigil)?	☐ Yes ☐ No
(if narcolepsy) Is there documentation that your patient has had daily periods of irrepressible need to sleep or lapses waking hours, occurring for at least three months? (if narcolepsy) Did your patient have a nocturnal polysomnography (PSG) to rule out other causes of excessive dayting	☐ Yes ☐ No
(if narcolepsy) Did your patient have a multiple sleep latency test (MSLT) that showed a mean sleep latency of 8 minutes (MSLT) and showed a mean sleep latency of 8 minutes (MSLT) and showed a mean sleep latency of 8 minutes (MSLT) and showed a mean sleep latency of 8 minutes (MSLT) and showed a mean sleep latency of 8 minutes (MSLT) and showed a mean sleep latency of 8 minutes (MSLT) and showed a mean sleep latency of 8 minutes (MSLT) and showed a mean sleep latency of 8 minutes (MSLT) and showed a mean sleep latency of 8 minutes (MSLT) and showed a mean sleep latency of 8 minutes (MSLT) and showed a mean sleep latency of 8 minutes (MSLT) and showed (MSLT) are showed (MSLT) and showed (MSLT) and showed (MSLT) are shown (MSLT) are showed (MSLT) are showed (MSLT) are showed (MSLT) are showed (MSLT) are shown (MSLT) are	
	□ Yes □ No
(if narcolepsy) Did your patient have any sleep-onset rapid eye movement periods (SOREMPs) during the MSLT? ☐ Yes, 2 or more SOREMPs ☐ Yes, only 1 SOREMP ☐ No or Unknown	☐ Yes ☐ No
☐ Yes, 2 or more SOREMPs ☐ Yes, only 1 SOREMP	
☐ Yes, 2 or more SOREMPs ☐ Yes, only 1 SOREMP ☐ No or Unknown	☐ Yes ☐ No ☐ Yes ☐ No for example, ☐ Yes ☐ No

Save Time! Submit Online at: www.covermymeds.com/main/prior-auth	orization-forms/cigna/ or via SureScripts in your EHR.
Prescriber Signature:	Date:
Attestation: I attest the information provided is true and accurate to the be insurer its designees may perform a routine audit and request the medical information reported on the second contraction of the second contraction in the second contraction of the second contraction o	cal information necessary to verify the accuracy of the
include the reason why they cannot use them]):	e to contrainaleation per 1 DA of Health reason (be sure to
Additional Pertinent Information: (please include details for each drug date(s) taken and for how long, and what the documented results were of taken patient experienced OR include any drugs your patient cannot take either du	king it, including any intolerances or adverse reactions your

Our standard reasonable time for prescription drug equations and parts in Educations down If your requirest in the important that

Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.

V040620

"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005